A family from Lancaster have received amazing support from the community after issuing an urgent plea for their epileptic son ...

William Blair has hand-picked its top five stock recommendations for 2026, selections that include three clinical-stage ...

NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that it has filed a Premarket Approval Supplement (PMA-S) ...

Learn more about whether Catalyst Pharmaceuticals, Inc. or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Individuals with focal onset epilepsy treated with azetukalner experienced sustained monthly seizure reduction and evidence of seizure freedom up to 48 months, according to data presented at the ...

A woman told when she was 21 that she wouldn't live beyond 40 says her husband has had to save her life multiple times - and one time she floated out of her body and saw her grandpa, and her younger ...

Ann-Louise has a rare life-limiting condition, but lights up when she sings. As our Mirror Christmas appeal for Lifelites ...

Xenon Pharmaceuticals (XENE) is undervalued given azetukalner's late-stage potential to transform epilepsy and mood disorder ...

Many people living with focal onset seizures (FOS) fail to achieve seizure freedom, even after taking two or more ...

Nocturnal seizures often cause symptoms like spasms, grunting, and breathing difficulties while sleeping. Increasing sleep by 90 minutes can decrease your seizure risk by 27% over 48 hours.

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

Epilepsy refers to a group of neurological disorders of varying aetiology, characterized by recurrent brain dysfunction that result from sudden excessive and disordered neuronal discharge. These ...